Monday pre-open / early-session briefing

Aman's Global Market Intelligence — 2026-09-28

Generated 08:30 CEST (Europe/Rome) · Data cutoff 08:30 CEST / 06:30 UTC · Asian cash markets near/at close, Europe pre-open futures, live overnight U.S. futures and rates/commodities; U.S. cash closes are Friday 25 Sept.

RISK-OFF — OIL + YIELDS OVERRIDE FRIDAY'S EQUITY BOUNCE

Trump's rejection of Iran's proposal pushed Brent back near $107, Treasury yields higher and Nasdaq futures down about 0.7%. With October Fed-hike odds near 69%, long-duration AI, quantum and clinical biotech require confirmation, not dip-buying by reflex. At 08:30 Italy, European cash markets and most U.S. releases have not opened/printed.

Executive dashboard

S&P 5007,743.41+0.51% Fri · futures −0.3%
Nasdaq Comp.27,068.72+0.48% Fri · futures −0.7%
Dow51,828.62+0.93% Fri
Russell 20002,837.55+0.07% Fri
VIX14.87−5.11% Fri close
U.S. 2Y4.91%+4.4 bp live snapshot
U.S. 10Y5.21%+3.2 bp live snapshot
Dollar index101.2–101.4two-month area
WTI / Brent$94.16 / $107.16+1.9% / +2.7%
Gold~$4,192−2.2% Reuters snapshot
Nikkei 22566,214−0.23%
Hang Seng24,673+0.66%
Shanghai / KOSPI−1.70% / −2.46%China/Korea risk-off
Euro Stoxx 50 fut.+0.3%pre-open indication
DAX / FTSE fut.+0.2% / +0.2%pre-open indications

Cross-check: Reuters overnight market report, CNBC market dashboard, Yahoo Markets and official Treasury curve. Live snapshots differ slightly by timestamp/contract: CNBC showed 10Y 5.213%, WTI $94.06 and gold $4,211.80; Reuters showed 10Y around the same risk direction, WTI $94.16 and spot gold $4,192. Friday official Treasury closes were 2Y 4.81% and 10Y 5.17%.

1 · Oil reopens the inflation tail

Brent's 2.7% rise after the U.S.–Iran setback threatens transport/input costs and makes the Fed path more hawkish. Energy is now the fastest macro transmission channel.

2 · 5%+ discount rate bites growth

Ten-year yields near 5.21% and a 69.2% October-hike probability directly compress long-duration valuations; quantum and pre-profit biotech are most exposed.

3 · Asia confirms dispersion

Hang Seng rose, but Shanghai fell 1.7% and KOSPI 2.46%; Chinese tech also faces fresh U.S. government-system restrictions. This is not synchronized risk-on.

Market drivers

Macro, rates & central banks

  • Fed: CME FedWatch showed a 69.2% probability of a 25 bp hike on Oct. 28 (data 01:15 CT), up from 57.6% one week earlier; current target is 3.75%–4.00%.
  • Curve: official Friday closes were 4.81% (2Y) and 5.17% (10Y); overnight market snapshots moved to roughly 4.91% and 5.21%. The 30Y near 5.52% is close to levels last seen in 2004.
  • Growth: Reuters cites Atlanta Fed GDPNow at 5.0% for Q3, supporting earnings but also higher-for-longer rates.
  • Monday: Dallas Fed manufacturing is due 10:30 ET; 3M/6M bill auctions and Fed speakers follow. At publication these are future events, not results.

Geopolitics, rotation & breadth

  • Iran/Hormuz: the rejected proposal leaves crude supply and diesel inflation headline-sensitive. A credible reopening path is the clearest risk-on reversal trigger.
  • China: CSI 300 fell about 1.9% to a one-year low in Reuters' snapshot after lawmakers proposed barring Chinese-made AI data-center transmission components from sensitive U.S. systems.
  • Friday breadth: Dow outperformed Nasdaq and Russell; quality/cash-flow beat broad beta. Monday futures reverse some of the relief.
  • Europe: index futures are mildly positive, but a stronger dollar, expensive energy and global yields leave the pre-open signal fragile.

Theme dashboards

AI / semis / cloud / power

Fundamental strength, macro stress
  • Leaders: Friday's U.S. movers included Bloom Energy +8.27%, ON Semi +5.54%, Microchip +5.36% and Dell +5.01% (CNBC). They are prior-session moves, not Monday indications.
  • Quality evidence: NVIDIA reported Q2 FY27 revenue $96.2bn (+106% y/y), Data Center $89.0bn (+117%) and guided Q3 revenue to $108bn ±2%, excluding China Data Center compute (NVDA IR).
  • Networking/custom silicon: Broadcom reported Q3 AI semiconductor revenue $16.7bn (+221% y/y), Q4 AI revenue outlook $21.7bn and consolidated revenue guide $34.8bn (AVGO IR).
  • Laggards/risk: Korea's SK Hynix fell 4.35% and Samsung 4.99% in Yahoo snapshots. Rising funding costs, power constraints, customer concentration, exports and AI-ROI scrutiny can overwhelm strong revenue.

Quantum computing & suppliers

Extreme / venture-like risk
  • Verified milestone: IonQ plans a Superion 256 installation at NVIDIA's NVAQC in 2027, linked to GB200 NVL72 via NVQLink; first customer deliveries are expected in 2027 (IONQ IR).
  • Critical caveat: the release discloses architecture and research goals, not contract value, recurring revenue or customer acceptance economics.
  • QUBT catalyst: Quantum Computing Inc. lists the Quantum Innovation Summit Sept. 28–30 and recent secure-communications/framework announcements (company news); conference visibility is not revenue validation.
  • Risk: 5%+ yields, low current revenue, dilution, roadmap slippage, acquisitions and severe momentum reversals. Treat IONQ/QUBT/RGTI/QBTS as speculative, not core holdings.

Peptide-drug biotech

Strong science, binary execution
  • VK2735 evidence: randomized double-blind placebo-controlled maintenance study (~180 adults, BMI ≥30) used 21-week induction plus 12-week maintenance. Weekly dosing produced ~16%–19% loss at week 21 (p<0.0001); every-other-week maintained up to 97% and monthly up to 90% versus 61% placebo; GI event rates during maintenance were reported similar to placebo (VKTX IR).
  • Statistics caveat: weight-maintenance endpoints were exploratory; one monthly analysis excluded an outlier >2.5 SD from the cohort mean. Sponsor topline is not peer review or regulatory assessment.
  • Path: Viking says VK2735 is in Phase 3. Approval still requires confirmatory efficacy/durability, larger safety exposure, manufacturing and FDA review; it competes with Lilly/Novo and next-generation incretin/amylin programs.
  • Cash/dilution: financing improves runway but adds supply. Do not infer adequate runway from clinical efficacy alone; the next 10-Q is the cash baseline.

Ranked ideas — paper-tracked, confirmation only

No compelling unconditional bullish entry. The regime shift since Sunday makes capital preservation the highest-ranked action. Two avoids and five watches follow; scores measure evidence/setup quality, not guaranteed probability.

Bearish / avoid

#1 MU — avoid pre-earnings chase

Event + duration risk

NASDAQ · Large-cap memory semiconductor · Very high risk · Classification: avoid new long, not a short · Horizon: day through Sept. 30 and 1–4 weeks · Direction uncertain/gap-prone.

Thesis/catalyst: fiscal Q4 results are Wednesday after the close, into surging yields and an unusually high expectation bar. Evidence: Friday close $1,082.28; official call is Sept. 30 at 2:30 p.m. MT (Micron IR). Counterargument: HBM/DRAM scarcity and AI demand can still drive a beat-and-raise.

Entry / confirmationNo pre-event entry. Requalify only after results/guidance and a close above $1,110 on strong volume; otherwise wait for a higher low.
Invalidation / downsideAvoid thesis invalidates on guide-backed acceptance above $1,110. Below $1,045 weakens; below $1,020 invalidates the tactical trend. Gaps can overrun levels.
Fundamental lensStrong earnings power, but memory is cyclical; watch pricing, HBM mix, capex and gross-margin sustainability rather than headline EPS alone.
Key risksEvent gap, export policy, customer concentration, supply response, multiple compression and being underexposed if the guide surprises higher.

#2 IONQ — avoid momentum chase

Speculative duration

NYSE · Mid-cap quantum platform · Extreme risk · Classification: avoid chasing, not a short · Horizon: day and 1–4 weeks only · Direction uncertain; squeeze/gap risk.

Thesis: Friday's $45.48 price and NVIDIA validation are vulnerable to a 5.2% 10Y because disclosed deployment economics are absent and delivery begins in 2027. Evidence: primary release specifies the QPU/GB200 architecture but no contract value. Counterargument: ecosystem leadership and technical milestones can sustain speculative relative strength.

Entry / confirmationNo opening chase. Watch only after $43–44 holds and yields ease, or a close above $46.55 with exceptional volume and sector breadth.
Invalidation / downsideAvoid view weakens on accepted breakout above $46.55. Below $41 damages momentum; below $39 invalidates the prior setup. Extreme gaps remain possible.
Fundamental lensAssess bookings-to-revenue conversion, cash burn, dilution, acquired-business integration and independently reproduced performance—not qubit count alone.
Key risksRoadmap failure, commercialization delay, dilution, acquisition complexity, high valuation, illiquidity in stress and upside squeeze. No borrow availability/fee assumed.

Watchlist — not active until confirmed

1 · NVDA — quality AI leader

Conditional positive

NASDAQ · Mega-cap semiconductor · High risk · Classification: watch · Horizon: day, 1–4 weeks and 3–12+ months. Thesis: $108bn guide and 117% Data Center growth support leadership. Counter: 5.2% 10Y, China exclusion, concentration, margin/ROI risk. Entry: reclaim/close above $230 with SOX breadth, or a controlled $220–223 higher low after yields stop rising. Invalidation: below $220 weakens; below $214 ends the tactical setup. Risks: exports, supply, competition, capex digestion and valuation.

2 · AVGO — custom AI/networking cash flow

Conditional positive

NASDAQ · Mega-cap semiconductor/software · High risk · Classification: watch · Horizon: 1–4 weeks and 3–12+ months. Thesis: AI semiconductor growth, 46% FCF margin and $21.7bn Q4 AI revenue outlook are unusually strong. Counter: expectations, customer concentration, $57bn long-term debt and rate sensitivity. Entry: only after 10Y stabilizes and AVGO holds the first-hour range while outperforming SOX; no blind open. Invalidation: close below Friday's low with rising volume or Q4 AI guide slippage. Risks: custom-silicon concentration, VMware execution, exports, leverage and multiple compression.

3 · LLY — retatrutide / EASD watch

Clinical catalyst

NYSE · Mega-cap pharma · Medium/high risk · Classification: watch · Horizon: 1–4 weeks and 3–12+ months; avoid pre-data day trade. Thesis: EASD details can strengthen the Phase 3 triple-agonist profile. Counter: valuation, GI/sensory adverse events, discontinuation, access and Novo/other competition. Entry: post-presentation higher low or hold above $1,190; inspect estimand, confidence intervals and safety first. Invalidation: below $1,145 weakens and below $1,120 invalidates swing. Regulatory path: no retatrutide approval; Phase 3 package, manufacturing and FDA review remain. Risk: endpoint detail can gap the stock.

4 · VKTX — differentiated maintenance, financing overhang

Small-cap clinical biotech

NASDAQ · Small-cap clinical biotech · Extreme risk · Classification: speculative watch/avoid until supply clears · Horizon: 1–4 weeks only; 3–12+ months binary. Thesis: Phase 3 VK2735 plus up-to-monthly maintenance could differentiate. Evidence: ~180-person study, p-values and safety summarized above. Counter: exploratory endpoints, short maintenance window, sponsor analysis, one outlier exclusion and financing. Entry: financing settlement plus two closes above $38; stronger above $40. Invalidation: below $35 exposes $32–33; below $32 ends setup. Cash/runway: verify cash and quarterly burn in next 10-Q; new capital is runway and dilution. Risks: Phase 3 replication, GI/safety, FDA, manufacturing, competition and binary gaps.

5 · VRT — data-center power/cooling

Rate-sensitive recovery

NYSE · Large-cap infrastructure · High risk · Classification: watch · Horizon: day, 1–4 weeks and conditional 3–12+ months. Thesis: AI power/cooling buildout is structural; Friday +3.25% to $253.28 reclaimed $250. Counter: Monday oil/yields pressure capital-intensive growth and the intermediate trend is not fully repaired. Entry: two closes above $256; stronger above $266 with infrastructure breadth and stable 10Y. Invalidation: below $245 weakens; below $240 ends recovery. Risks: customer capex timing, execution, margins, competition, project finance and rates.

Changes versus the 2026-09-27 report

  • Regime downgraded: from neutral tape/risk-off rates to outright risk-off as Brent jumped, yields rose and Nasdaq futures fell 0.7%.
  • New executable information: Sunday had no futures; Monday now has negative U.S. index futures and divergent Asian closes. Europe is only mildly positive pre-open.
  • Fed risk increased: October hike odds moved to 69.2% from 57.6% one week ago; the 10Y live snapshot is above Friday's 5.17% official close.
  • IONQ downgraded: from speculative watch to avoid-chasing; technical triggers remain but require yield stabilization.
  • MU avoid retained; NVDA/LLY/VRT/VKTX remain conditional. AVGO replaces ANET because primary-source AI revenue, free cash flow and forward guidance provide stronger evidence in a risk-off tape.

Important 7–30 day catalysts

Sept. 28, 10:30 ET — Dallas Fed manufacturing; 08:30 Italy publication precedes the release.
Sept. 28–30 — Quantum Innovation Summit; QUBT lists attendance. Treat demonstrations/frameworks separately from booked revenue.
Sept. 28–Oct. 2 — EASD, Milan: metabolic/peptide presentations; Lilly retatrutide detail is a high-expectation clinical catalyst.
Sept. 29, 10:00 ET — August JOLTS and Consumer Confidence; labor resilience can move hike odds.
Sept. 30, 08:30 ET — Q2 GDP third estimate and August Personal Income & Outlays/PCE (BEA schedule).
Sept. 30 after close — Micron fiscal Q4 call, 2:30 p.m. MT (MU IR).
Oct. 1–2 — ISM manufacturing, then September payrolls; prices paid and wage data matter more with oil elevated.
Oct. 6, 08:30 ET — August U.S. international trade (BEA).
Oct. 27–28 — FOMC decision; CME currently prices a hike as the more likely outcome (Fed calendar).

Bottom line by horizon

Day trade

Plan: do not buy the opening dip automatically. Require 10Y/WTI stabilization and semiconductor breadth; avoid MU/LLY event front-running. Biggest risk: Iran/oil headline gap. Invalidation of defensive bias: Nasdaq futures recover, 10Y falls below 5.17% and Russell/SOX lead.

1–4 week swing

Plan: reduced size/cash reserve through PCE, payrolls and MU. Prefer NVDA/AVGO only after trend confirmation; VKTX/IONQ are not normal-risk positions. Biggest risk: inflation forces additional hikes. Invalidation: lower oil, falling yields and broad higher lows.

3–12+ month investment

Plan: stage cash-generative AI/networking/power leaders; treat quantum and clinical biotech as venture-like allocations. Biggest risk: earnings/cash flow fail to outrun the discount rate. Invalidation: estimate cuts, AI-capex digestion, roadmap slippage, trial failure or financing stress.

Data quality & methodology

Evidence controls

  • Research included 15+ live retrievals across Reuters/CNBC/Yahoo, Treasury/CME/Fed/BEA, SEC data, and NVIDIA/Broadcom/Micron/IonQ/QUBT/Viking primary pages.
  • Live market values are timestamped snapshots; Friday closes are not labeled as Monday prices. Reuters/CNBC/Yahoo differences are shown rather than silently reconciled.
  • Company/trial claims use primary releases. Sponsor results are explicitly separated from peer review and FDA assessment.
  • Technical levels are conditional paper-tracking levels carried from Friday's verified close dataset. No analyst ratings, targets, estimates, borrow availability or fees are invented.
  • Confidence = evidence quality; Risk rises with danger; Opportunity = risk-adjusted setup quality.

Known limitations / blocked sources

  • Yahoo chart API returned HTTP 429; accessible Yahoo Markets HTML and CNBC/Reuters supplied cross-checks.
  • Stooq CSV returned a JavaScript proof-of-work challenge for SPX/Nasdaq/NVDA; it was not used.
  • BLS direct retrieval returned HTTP 403 and web extraction later rate-limited; scheduled labor events were cross-checked against the prior official BLS retrieval and Reuters' current calendar. No unretrieved actual is reported.
  • Individual U.S. premarket ticker quotes were not used because a consistent, timestamped batch was unavailable. Entries therefore require live confirmation after U.S. liquidity develops.
  • European figures are futures indications because 08:30 Rome precedes major cash opens.

Sources

  1. Reuters: Stocks slip in Asia as oil and yields climb — overnight futures, Asia, rates, FX, commodities, geopolitics.
  2. CNBC Markets and Yahoo Markets — index, rates, commodity and regional cross-checks.
  3. U.S. Treasury daily curve — official Sept. 25 closes.
  4. CME FedWatch — Oct. 28 target-rate probabilities as of 01:15 CT.
  5. Federal Reserve FOMC calendar; BEA release schedule.
  6. NVIDIA Q2 FY27 results.
  7. Broadcom Q3 FY26 results.
  8. Micron earnings event notice.
  9. IonQ–NVIDIA NVAQC release; QUBT news/events.
  10. Viking VK2735 maintenance topline.
  11. SEC EDGAR: NVIDIA filings — filing cross-check.